Study: NCT00703014

Intervention type: DRUG
Intervention: Corifollitropin Alfa 150 μg
Description: In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.

Intervention type: BIOLOGICAL
Intervention: 200 IU RecFSH/Follitropin beta (Days 1 to 7)
Description: In the Base Trial P05787, daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.

Intervention type: DRUG
Intervention: Placebo for Corifollitropin Alfa
Description: In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection from a pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa was administered in the abdominal wall.

Intervention type: DRUG
Intervention: Placebo for RecFSH/Follitropin beta
Description: In the Base Trial P05787, daily SC injections of an identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen, were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.

Intervention type: BIOLOGICAL
Intervention: 200 IU RecFSH/Follitropin beta (Days 8 to hCG)
Description: In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.

Intervention type: BIOLOGICAL
Intervention: 200 IU RecFSH/Follitropin beta (Days 8 to hCG)
Description: In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.

Intervention type: DRUG
Intervention: Ganirelix
Description: In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.

Intervention type: DRUG
Intervention: Ganirelix
Description: In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.

Intervention type: BIOLOGICAL
Intervention: hCG
Description: In the Base Trial P05787, when 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP

Intervention type: BIOLOGICAL
Intervention: hCG
Description: In the Base Trial P05787, when 3 follicles \>= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP

Intervention type: BIOLOGICAL
Intervention: Progesterone
Description: In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.

Intervention type: BIOLOGICAL
Intervention: Progesterone
Description: In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.